Core Insights - Klotho Neurosciences, Inc. has partnered with AAVnerGene Inc. to enhance the manufacturing of its gene therapy candidates, aiming for faster, cost-effective, and higher efficacy treatments for neurodegenerative diseases [1][2] - The collaboration focuses on several product candidates, including KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS, and KLTO-303 for age-related pathologies [2] Company Overview - Klotho Neurosciences, Inc. specializes in innovative cell and gene therapies derived from the human Klotho gene, targeting neurodegenerative and age-related disorders [3] - The company is managed by a team experienced in biopharmaceutical product development and commercialization [3] AAVnerGene Overview - AAVnerGene is a biotechnology company that focuses on next-generation AAV vector technologies, including the AAVone system for cost-effective AAV production and the ATHENA platform for precise tissue targeting [2] - The company aims to provide affordable and scalable gene therapy solutions to accelerate clinical development across various therapeutic areas [2]
Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets